AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction
Start Date
2/19/2026
Completion Date
1/1/2028
Summary
The purpose of this study is to assess the efficacy and safety of single injection dose of AURN001 compared with placebo in adult participants with corneal edema secondary to corneal endothelial dysfunction.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Combination Product: AURN001 + Y-27632
Placebo
Conditions
Locations
Investigational Site 2
Mesa, Arizona 85206
United States
Investigational Site 6
Little Rock, Arkansas 72205
United States
Investigational Site 9
Fort Collins, Colorado 80528
United States
Investigational Site 7
Atlanta, Georgia 30339
United States
Investigational Site 4
Kansas City, Missouri 64154
United States
Investigational Site 11
Leland, North Carolina 28451
United States
Investigational Site 5
Winston-Salem, North Carolina 27157
United States
Investigational Site 3
Cynwyd, Pennsylvania 19004
United States
Investigational Site 10
Plymouth Meeting, Pennsylvania 19462
United States
Investigational Site 12
Ladson, South Carolina 29456
United States
Investigational Site 8
San Antonio, Texas 78209
United States
Investigational Site 1
Spring, Texas 77388
United States